Interleukin-19 is cardioprotective in dominant negative cyclic adenosine monophosphate response-element binding protein-mediated heart failure in a sex-specifc manner Danielle R Bruns, Alexander R Ghincea, Christian V Ghincea, Yasu-Taka Azuma, Peter A Watson, Michael V Autieri, Lori A Walker Danielle R Bruns, Alexander R Ghincea, Christian V Ghincea, Lori A Walker, Division of Cardiology, Department of Medicine, University of Colorado-Denver, Aurora, CO 80045, United States Yasu-Taka Azuma, Laboratory of Veterinary Pharmacology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Science, Osaka 599-8351, Japan Peter A Watson, Department of Medicine and Endocrinology, University of Colorado-Denver, Aurora, CO 80045, United States Peter A Watson, Denver Veterans Affairs Medical Center, Denver, CO 80220, United States Michael V Autieri, Independence Blue Cross Cardiovascular Research Center, Department of Physiology, Temple University School of Medicine, Philadelphia, PA 19122, United States Author contributions: Bruns DR was involved in conception and design of research, collected, analyzed, and interpreted data, and drafted the manuscript; Ghincea AR and Ghincea CV collected data; Azuma YT approved the fnal manuscript; Watson PA was involved in conception and design of research; Autieri MV contributed to intellectual design of research, edited and revised fnal manuscript; Walker LA was involved in conception and design of research, interpretation of data, editing, revising, and approval of fnal manuscript. Supported by The University of Colorado-Denver Center for Women’s Health Research (to Walker LA); NIH NHLBI HL007822-19 (to Bruns DR); NIH NHLBI HL117724 (to Autieri MV); NIH NHLBI HL115575 (to Autieri MV). Institutional review board statement: Human subjects research is governed by the Colorado Multiple Institutional Review Board (COMIRB # IORG0000433). However, no human subjects were included in this research. Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Colorado-Denver [Protocol # B-78616(05)1D]. Conflict-of-interest statement: The authors declare that they have no competing interests. Data sharing statement: Complete dataset and statistical analyses available from the corresponding author at lori.walker@ucdenver. edu. Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Lori A Walker, PhD, Division of Cardiology, Department of Medicine, University of Colorado-Denver, 12700 E. 19 th Ave, Aurora, CO 80045, United States. lori.walker@ucdenver.edu Telephone: +1-303-7245420 Received: January 11, 2017 Peer-review started: January 16, 2017 First decision: April 17, 2017 Revised: July 19, 2017 Accepted: July 21, 2017 Article in press: July 24, 2017 Published online: August 26, 2017 Abstract AIM To investigate the role of interleukin-19 (IL-19) in a murine model of female-dominant heart failure (HF). ORIGINAL ARTICLE Submit a Manuscript: http://www.f6publishing.com DOI: 10.4330/wjc.v9.i8.673 673 August 26, 2017|Volume 9|Issue 8| WJC|www.wjgnet.com World J Cardiol 2017 August 26; 9(8): 673-684 ISSN 1949-8462 (online) World Journal of Cardiology WJC Basic Study